Cases must be submitted at least seven days prior to the meeting date.

Genomics reports from any testing laboratory (Caris, Foundation, Guardant, Tempus, etc.) can be submitted. A patient's genomic report is required for case submission. 

• If your facility uses UK's EpicCare Link, please submit a case using the “Ambulatory Referral to Molecular Tumor Board" order. Please ensure a copy of the genomic report is submitted with the order.
• If your facility does not use EpicCare Link, please fill out the case submission form online, or download the form below. 
  • Download form
  • The patient’s genomic report can be sent to MTB by email.
  • Learn more about EpicCare Link, and setup an EpicCare Link account.

When the case submission and genomic report are received, the MTB manager will schedule the case for presentation and invite the treating clinician to the meeting.

Treatment recommendations will be discussed at the MTB meeting. Recommendation letters will be faxed, sent by secure e-mail, mailed or uploaded into the electronic health record per the preference of the submitting physician.Specify method of results reporting on the case submission form.

Note: There is no cost to submit a case to the Markey Cancer Center Molecular Tumor Board.

The molecular tumor board will review genomic reports from any testing laboratory. If you need assistance with ordering genomic testing, please reach out to your laboratory representative. You can contact the MTB if you have general questions.

Genomic reports for patients with hematologic malignancies can be ordered through the Clinical Molecular and Genomic Pathology department. There are some gene-specific hematological panels as well as a larger hematological malignancy panel.

Please see more information about our clinical genomics laboratory by visiting the department's website.

Guidance documents are used to establish guidelines for Molecular Tumor Board (MTB) recommendations for advanced cancer.

MTB guidance documents will be made available to download below.

Download Guidance MTB Documents

• Guidance Document: Off-Label Use (PDF, 114.17 KB)

Reference documents are used to aid Molecular Tumor Board members in meeting discussions and advanced care recommendations.

MTB reference documents will be made available for download below on this page.

Download MTB Documents

• Navigating from Somatic Tumor Testing to Germline Genetic Testing – MTB Meeting, March 21, 2017 (PDF)

Watch MTB presentations

• Next Generation Sequencing: What They Are & When to Order Them
• Intro to MCC Clinical Practice Guidelines

The Molecular Tumor Board currently has three prospective clinical trials evaluating integration of Precision Medicine into cancer therapeutics.

• MULTI-19 Part 1: A prospective observational cohort study evaluating outcomes of genomic testing in patients with poor prognosis cancer.
• MULTI-19 Part 2: A therapeutic phase 2 sub-study evaluating genomic testing in human cancer and outcomes of targeted therapies recommended by an institutional multidisciplinary molecular tumor board in patients with poor prognosis cancer.
• PRiMAL: A prospective study for patients with newly-diagnosed non-small cell lung cancer (NSCLC) evaluating outcomes for patients undergoing usual care compared to those where the MTB is actively involved in patients’ care.

Researchers who are interested in using the data or specimen collected under these protocols must complete the data request form.

Publications

• Clinical Utility of Molecular Tumor Board Review for Identification of Possible Germline Pathogenic Variants on Tumor Next-Generation Sequencing Reports
• Implementation of Nurse Navigation Improves Rate of Molecular Tumor Testing for Ovarian cancer in a Gynecologic Oncology Practice
• Next Generation Sequencing and Molecular Biomarkers in Ovarian Cancer – An Opportunity for Targeted Therapy
• Clinical Outcomes of Molecular Tumor Boards: A Systematic Review
• Molecular Tumor Board Review and Improved Overall Survival in Non-Small-Cell Lung Cancer
• Feasibility and Clinical Utility of Reporting Hereditary Cancer Pathogenic Variants Identified in Research Germline Sequencing: A Prospective Interventional Study
• Bridging the Biomarker Chasm with Interprofessional Molecular Tumor Boards
• Molecular Tumor Board-Assisted Care in an Advanced Cancer Population: Results of a Phase II Clinical Trial
• Real-World Evaluation of a Population Germline Genetic Screening Initiative for Family Medicine Patients
• Real-World Evaluation of Universal Germline Screening for Cancer Treatment-Relevant Pharmacogenes